VA-MODUS-CREATE
10.1.2023 14:04:38 CET | Business Wire | Press release
Modus Create, a digital transformation consulting firm, announced today that it has acquired Clarisoft, a Romanian software engineering company with deep expertise in custom product development for enterprises.
This is Modus Create’s fifth acquisition in the last 12 months, topping off a year of accelerated growth and inclusion on the Inc. 5000 list for the eighth successive time. Since May, Modus Create has expanded its offerings through the acquisitions of software engineering company Tweag; product development firm Promptworks; and Atlassian consulting firms Atlas Authority and Twybee. The acquisition of Clarisoft represents Modus Create’s third acquisition in the European market.
Headquartered in Bucharest, Romania, Clarisoft is known for building quality software across enterprise, mid-market, and government clients worldwide, particularly in sectors such as healthcare, automotive, finance, and telecom. Its clients include organizations such as Cisco and Livongo Health.
Clarisoft’s CEO Bogdan Bucura will join Modus in a sales leadership role, and Development Director Mircea Enache will take on a delivery leadership role. Also joining Modus will be 40 senior engineers, designers, and project managers.
“We continue to add capabilities and talent that deepen Modus Create’s expertise as a leading global partner for product development. Adding Clarisoft to the team expands our European footprint and strengthens our offerings in enterprise software development, leading cloud platforms, and microservices delivery,” said Sarah McCasland, Chief Strategy Officer, Modus Create. “Most importantly, Clarisoft is a cultural fit that will seamlessly integrate with the Modus values of creating high-quality products for our clients.”
“By joining Modus Create, I saw an opportunity for Clarisoft to be a part of a bigger organization while still providing the type of service our clients expect,” said Bogdan Bucura, CEO, Clarisoft. “We will bring expertise in areas such as Microsoft Azure, broadening the scope of Modus’ already highly respected software engineering team. And we look forward to offering our clients the broader services Modus has in areas such as platform modernization and digital operations.”
About Modus Create
Modus Create is a digital consulting firm dedicated to helping clients build competitive advantage through digital innovation. We support organizations across their transformation journey with strategic consulting and full lifecycle product development. Our global team of strategists, designers, and technologists has created powerful digital experiences for some of the world’s biggest brands. Visit moduscreate.com to learn more.
About Clarisoft
Clarisoft Technologies is a top software development company with offices in Europe and the USA. We offer full-stack digital solutions for business and staff augmentation through outsourcing services in Romania. We provide high-quality and cost-effective custom software development and mobile application development services for enterprises.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005166/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom